Home

Ivan P. Gergel

CIK 1328288 · SVP & Chief Medical Officer · last filed 2020-12-03

Ivan P. Gergel is a SVP & Chief Medical Officer who has filed 50 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for NTRP, was dated Dec 3, 2020. Across all open-market trades the lifetime net is −$21.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $234.2K across reported positions. 18 SEC filings were submitted jointly with ENDO PHARMACEUTICALS HOLDINGS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$234.2K

Companies

5

Total Filings

50

Lifetime Open-Market Net

-$21.05M

Filer Profile

Reported Address
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BLVD SOUTH
SAN FRANCISCO, CA 94158
Formerly Known As
Gergel Ivan (2005–2008)
Related Filers
ENDO PHARMACEUTICALS HOLDINGS INC — 18 joint filings, latest 2014-03-03
FOREST LABORATORIES INC — 8 joint filings, latest 2008-01-29
Endo International plc — 1 joint filings, latest 2014-03-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NTRP Director — $1.93 — $0 6 2020-12-03
Corium International, Inc. (CORI) Delisted Director — — — $0 5 2018-11-28
NKTR SVP & Chief Medical Officer 4,105 $57.06 $234.2K -$4.66M 17 2017-11-17
Endo International plc (ENDP) Delisted EVP, R&D and CSO 34,256 $0.29 $10.0K -$14.67M 18 2014-03-11
Forest Laboratories, LLC (FRX) Delisted Sr VP - Chief Sci. Officer 15,000 $12.00 $180.0K -$1.72M 4 2008-01-29

Recent Filings

50 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-12-03 NTRP Disp (D) — $0 EDGAR
2020-11-27 NTRP Grant (A) — $0 EDGAR
2020-03-24 NTRP Grant (A) — $0 EDGAR
2019-04-15 NTRP Grant (A) — $0 EDGAR
2019-01-24 NTRP Grant (A) — $0 EDGAR
2018-12-17 NTRP Grant (A) — $0 EDGAR
2018-11-28 Corium International, Inc. (CORI) Delisted Disp (D) — $0 EDGAR
2017-12-05 Corium International, Inc. (CORI) Delisted Grant (A) — $0 EDGAR
2017-11-17 NKTR Mixed +14,978 -$222.1K EDGAR
2017-10-03 NKTR Mixed — -$1.31M EDGAR
Showing 1–10 of 50
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.